南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停

口腔鳞状细胞癌患者来源类器官生物库揭示CDCP1介导顺铂耐药机制

A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma

Yuhan Wang, Pengfei Diao, Pin Lv, Na Qi, Ziyu Wang, Enshi Yan, Jin Li, Yanling Wang, Dongmiao Wang, Yaping Wu, Jie Cheng

Journal:Cell Reports Medicine

IF:14

DOI:10.1016/j.xcrm.2026.102622

PMID:41707653

Published:2026-02-17

research field:肿瘤学分子生物学癌症研究精准医学药理学类器官技术纳米医学

Abstract

Oral squamous cell carcinoma (OSCC) remains a significant clinical challenge due to frequent recurrence, metastasis, and therapeutic resistance. Here, we establish a living biobank of OSCC patient-derived organoids (PDOs) comprising 46 lines using optimized culture medium. These PDOs are long-term passaged, cryopreserved, and recovered with stable viability and tumorigenicity. Comprehensive morphological, genomic, and transcriptomic analyses confirm that PDOs faithfully recapitulate the histopathological, genetic, and molecular features of parental tumors. These PDOs enable disease modeling, genetic manipulation, and drug screening. Through transcriptomic profiling and functional assays, we find that CDCP1 mediates cisplatin resistance by modulating Wnt/β-catenin signaling-driven stemness. Notably, we develop a pH-sensitive nanoparticle delivering siCDCP1, which effectively restores chemosensitivity and impairs tumor growth in cisplatin-resistant patient-derived xenograft (PDX) models with favorable safety profile. These findings establish PDOs as robust preclinical models for mechanistic explorations and therapeutics development and highlight CDCP1-targeting strategies as promising approaches to overcome cisplatin resistance in OSCC.

本文使用的Yeasen产品

购物车
客服
转染试用